Royce & Associates LP Grows Holdings in Astrana Health, Inc. $ASTH

Royce & Associates LP grew its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 34.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 348,331 shares of the company’s stock after buying an additional 88,978 shares during the quarter. Royce & Associates LP’s holdings in Astrana Health were worth $8,642,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Signaturefd LLC grew its stake in Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock worth $26,000 after buying an additional 388 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Astrana Health by 144.7% in the 4th quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock valued at $37,000 after purchasing an additional 871 shares in the last quarter. Strs Ohio purchased a new stake in shares of Astrana Health in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC boosted its stake in shares of Astrana Health by 323.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Astrana Health in the 2nd quarter valued at $132,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Trading Down 0.5%

NASDAQ:ASTH opened at $38.33 on Friday. The company has a fifty day moving average of $31.83 and a 200 day moving average of $26.32. Astrana Health, Inc. has a 52 week low of $18.08 and a 52 week high of $39.93. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $2.14 billion, a P/E ratio of 62.84 and a beta of 0.98.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45. Astrana Health had a net margin of 0.86% and a return on equity of 9.22%. The company had revenue of $965.10 million during the quarter, compared to analyst estimates of $949.21 million. During the same period in the prior year, the business posted $0.42 EPS. The firm’s revenue was up 55.6% compared to the same quarter last year. On average, research analysts predict that Astrana Health, Inc. will post 1.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ASTH shares. Needham & Company LLC upped their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings raised shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Zacks Research raised shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 11th. Barclays raised shares of Astrana Health from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $37.00 to $50.00 in a research note on Tuesday. Finally, BTIG Research upped their price objective on shares of Astrana Health from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.00.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.